Navigation Links
Test for early detection of prostate cancer shows promise

In the first clinical study of a new blood protein associated with prostate cancer, researchers have found that the marker, called EPCA or early prostate cancer antigen, can successfully detect prostate cancer in its earliest stages. At the same time, the marker successfully avoids the problem of false positive results that plagues prostate-specific antigen (PSA) testing.

Study results appear in the May 15, 2005, issue of Cancer Research. The lead author is Robert H. Getzenberg, Ph.D., professor of urology and director of research at the James Buchanan Brady Urological Institute at Johns Hopkins.

The traditional two-step approach of PSA testing and digital rectal examination has helped doctors identify prostate tumors early, while the cancers can still be cured. But PSA testing, like many disease-screening procedures, misses some cases of cancer and in other cases erroneously highlights noncancerous conditions.

“This new blood test, when coupled with PSA screening, may help reduce the number of both unnecessary biopsies and undetected prostate tumors,?said Getzenberg, In addition to being highly sensitive to prostate cancer, the EPCA test is also very specific to it, meaning that other cancers and benign prostate conditions are not detected, thus boosting doctors?confidence that a positive EPCA test is really a sign of prostate cancer, added Getzenberg.

“Once this test is refined and approved for general use, it will have an impact on the detection and treatment of prostate cancer,?said Getzenberg.

For the current study, Getzenberg and colleagues developed a simple test that would detect EPCA in the blood and then measured the EPCA levels in 46 patients, including those with prostate cancer (12 patients), bladder cancer (six patients), colon cancer (two patients), kidney cancer (one patient), spinal cord injury (seven patients) and noncancerous prostate inflammation (two patients), and 16 healthy individuals. The study was cond ucted at the University of Pittsburgh while Getzenberg was a member of its faculty.

The researchers found that EPCA levels were high in 11 of 12 prostate cancer patients (92 percent) and low in all of the healthy individuals. Only two bladder cancer patients and none of the other patients had elevated EPCA levels, suggesting that for this study, the test was correct 94 percent of the time. For comparison, only one-quarter of patients who undergo biopsies because they have elevated PSA values are actually positive for prostate cancer, while as many as 15 percent of those with low PSA values were found to have prostate cancer as detected by biopsy, according to Getzenberg.

Larger clinical trials are under way to further refine the EPCA test, to make it more sensitive so it can pick up even the smallest traces of the marker, and to verify its usefulness for detecting prostate cancer in a larger sample of patients, said Getzenberg.

Prostate cancer is the most common type of cancer found in American men. The American Cancer Society estimates that there will be approximately 232,090 new cases of prostate cancer in the United States in 2005, and 30,350 men will die of this disease.

Funding for the study was provided by Tessera Inc. Other authors on the report are Barbara Paul, Rajiv Dhir, Douglas Landsittel and Moira Hitchens, all of the University of Pittsburgh.


'"/>

Source:Johns Hopkins


Related biology news :

1. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
2. Neuronal traffic jam marks early Alzheimers disease
3. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
4. In the migratory marathon, parasitized monarchs drop out early
5. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
6. Confocal imaging promises early detection of skin cancer
7. Measles Deaths Worldwide Drop By Nearly 40% Over Five Years
8. Oldest cranial, dental and postcranial fossils of early modern European humans confirmed
9. A whole lot of shaking goin on triggers early hatching in red-eyed tree frogs
10. New mitochondrial DNA gene chip may be early cancer diagnosis tool
11. MicroRNA tweaks protein that controls early heart development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
Breaking Biology Technology: